Pharmaceuticals, Biotechnology and Life Sciences
Amryt Pharma has published a long-term extension study of Lojuxta in treating a rare, genetic, life-threatening disease, Homozygous Familial Hypercholesterolaemia (HoFH), which followed patients for up to 5.7 years results, showed Lojuxta as being highly effective in lowering LDL-C levels, with acceptable tolerability and no new safety signals.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has enroled first patient into “EASE”, the company’s pivotal Phase 3 clinical trial, which is evaluating AP101 as a potential treatment for the rare, genetic skin disorder, Epidermolysis Bullosa (“EB”).
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has reported its final results for the year ended 31 December 2016.
Amryt has begun with “EASE”, the Phase 3 clinical trial of AP101, its lead drug candidate, which offers a potential treatment for a rare genetic skin disorder that causes fragile skin.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has appointed David Allmond as Chief Commercial Officer in a non-board capacity, with effect from 3 April 2017.
Amryt is on track to begin the phase 3 trial at the end of March for its new skin healing treatment in an orphan disease, with regulatory authority discussions now completed with Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the design of the clinical trial established.
Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.
Amryt, the clinical-stage specialty pharmaceutical company focused on fighting rare and orphan diseases, has raised a five-year €20m loan with…